ZA200704739B - Substituted cyclopentanes or cyclopentanones as therapeutic agents - Google Patents
Substituted cyclopentanes or cyclopentanones as therapeutic agentsInfo
- Publication number
- ZA200704739B ZA200704739B ZA200704739A ZA200704739A ZA200704739B ZA 200704739 B ZA200704739 B ZA 200704739B ZA 200704739 A ZA200704739 A ZA 200704739A ZA 200704739 A ZA200704739 A ZA 200704739A ZA 200704739 B ZA200704739 B ZA 200704739B
- Authority
- ZA
- South Africa
- Prior art keywords
- cyclopentanones
- therapeutic agents
- substituted cyclopentanes
- cyclopentanes
- substituted
- Prior art date
Links
- 150000001940 cyclopentanes Chemical class 0.000 title 1
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical class O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/74—Unsaturated compounds containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64406905P | 2005-01-14 | 2005-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200704739B true ZA200704739B (en) | 2009-10-28 |
Family
ID=36678136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200704739A ZA200704739B (en) | 2005-01-14 | 2007-06-18 | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7635716B2 (xx) |
| EP (1) | EP1846354B1 (xx) |
| JP (1) | JP5060311B2 (xx) |
| KR (1) | KR101227808B1 (xx) |
| CN (1) | CN101102989B (xx) |
| AR (1) | AR052876A1 (xx) |
| AT (1) | ATE465986T1 (xx) |
| AU (1) | AU2006205029B2 (xx) |
| BR (1) | BRPI0605926A2 (xx) |
| CA (1) | CA2593661A1 (xx) |
| DE (1) | DE602006013945D1 (xx) |
| DK (1) | DK1846354T3 (xx) |
| ES (1) | ES2343430T3 (xx) |
| HK (1) | HK1114601A1 (xx) |
| IL (1) | IL184025A (xx) |
| MX (1) | MX2007008188A (xx) |
| NZ (1) | NZ555945A (xx) |
| TW (1) | TWI379696B (xx) |
| WO (1) | WO2006076370A2 (xx) |
| ZA (1) | ZA200704739B (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| WO2007005176A1 (en) | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| WO2007149829A2 (en) | 2006-06-20 | 2007-12-27 | Allergan, Inc. | Therapeutic compounds |
| JP5532302B2 (ja) * | 2006-07-10 | 2014-06-25 | アラーガン インコーポレイテッド | 治療化合物 |
| US20080015219A1 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Therapeutic compounds |
| US7507817B2 (en) | 2006-11-17 | 2009-03-24 | Allergan, Inc. | Prostaglandin prodrugs |
| BRPI0806716A2 (pt) * | 2007-01-22 | 2011-09-06 | Allergan Inc | arilciclopentenos substituìdos como agentes terapêuticos |
| NZ582705A (en) * | 2007-07-03 | 2012-06-29 | Allergan Inc | Therapeutic substituted cyclopentanes for reducing intraocular pressure |
| US8158676B2 (en) * | 2007-11-29 | 2012-04-17 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| BRPI0911543A2 (pt) * | 2008-04-24 | 2015-10-13 | Allergan Inc | arilciclopentenos substituídos como agentes terapêuticos |
| PL3062775T3 (pl) | 2013-10-31 | 2018-05-30 | Allergan, Inc. | Implanty wewnątrzgałkowe zawierające prostamid i sposoby ich stosowania |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| WO2015175544A1 (en) | 2014-05-12 | 2015-11-19 | Allergan, Inc. | Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3980700A (en) | 1971-10-07 | 1976-09-14 | G. D. Searle & Co. | Prostaglandin intermediates and optically active isomers thereof |
| SE436037B (sv) * | 1976-04-30 | 1984-11-05 | Roussel Uclaf | Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| ATE390917T1 (de) | 1996-12-20 | 2008-04-15 | Pfizer | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
| AU7349298A (en) | 1997-06-23 | 1999-01-04 | Pfizer Inc. | Prostaglandin agonists |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| IL139941A0 (en) | 1999-12-02 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin agonists to treat erectile dysfunction or impotence |
| US6291522B1 (en) * | 2000-09-27 | 2001-09-18 | Allergan Sales, Inc. | Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| MXPA04004164A (es) | 2001-11-05 | 2004-09-06 | Allergan Inc | Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2. |
| MXPA04008596A (es) | 2002-03-05 | 2004-12-06 | Ono Pharmaceutical Co | Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo. |
| JPWO2004089411A1 (ja) | 2003-04-03 | 2006-07-06 | 小野薬品工業株式会社 | 脊柱管狭窄症治療剤 |
| US7323591B2 (en) * | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
| WO2007149829A2 (en) * | 2006-06-20 | 2007-12-27 | Allergan, Inc. | Therapeutic compounds |
-
2006
- 2006-01-10 AU AU2006205029A patent/AU2006205029B2/en not_active Ceased
- 2006-01-10 ES ES06717964T patent/ES2343430T3/es active Active
- 2006-01-10 EP EP06717964A patent/EP1846354B1/en not_active Not-in-force
- 2006-01-10 CA CA002593661A patent/CA2593661A1/en not_active Abandoned
- 2006-01-10 DE DE602006013945T patent/DE602006013945D1/de active Active
- 2006-01-10 NZ NZ555945A patent/NZ555945A/en not_active IP Right Cessation
- 2006-01-10 WO PCT/US2006/000831 patent/WO2006076370A2/en active Application Filing
- 2006-01-10 US US11/569,369 patent/US7635716B2/en not_active Expired - Fee Related
- 2006-01-10 BR BRPI0605926-0A patent/BRPI0605926A2/pt not_active IP Right Cessation
- 2006-01-10 AT AT06717964T patent/ATE465986T1/de not_active IP Right Cessation
- 2006-01-10 MX MX2007008188A patent/MX2007008188A/es active IP Right Grant
- 2006-01-10 JP JP2007551328A patent/JP5060311B2/ja not_active Expired - Fee Related
- 2006-01-10 KR KR1020077016073A patent/KR101227808B1/ko not_active IP Right Cessation
- 2006-01-10 DK DK06717964.8T patent/DK1846354T3/da active
- 2006-01-10 CN CN2006800022678A patent/CN101102989B/zh not_active Expired - Fee Related
- 2006-01-13 TW TW095101527A patent/TWI379696B/zh not_active IP Right Cessation
- 2006-01-13 AR ARP060100155A patent/AR052876A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 ZA ZA200704739A patent/ZA200704739B/xx unknown
- 2007-06-18 IL IL184025A patent/IL184025A/en not_active IP Right Cessation
-
2008
- 2008-04-22 HK HK08104465.0A patent/HK1114601A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK1846354T3 (da) | 2010-08-16 |
| BRPI0605926A2 (pt) | 2009-05-26 |
| IL184025A0 (en) | 2008-12-29 |
| JP2008526970A (ja) | 2008-07-24 |
| ES2343430T3 (es) | 2010-07-30 |
| WO2006076370A3 (en) | 2007-01-11 |
| US7635716B2 (en) | 2009-12-22 |
| MX2007008188A (es) | 2007-08-07 |
| KR101227808B1 (ko) | 2013-01-30 |
| WO2006076370A2 (en) | 2006-07-20 |
| CN101102989A (zh) | 2008-01-09 |
| ATE465986T1 (de) | 2010-05-15 |
| WO2006076370B1 (en) | 2007-02-22 |
| JP5060311B2 (ja) | 2012-10-31 |
| CA2593661A1 (en) | 2006-07-20 |
| EP1846354A2 (en) | 2007-10-24 |
| KR20070094919A (ko) | 2007-09-27 |
| TWI379696B (en) | 2012-12-21 |
| US20080058414A1 (en) | 2008-03-06 |
| TW200714312A (en) | 2007-04-16 |
| AU2006205029B2 (en) | 2012-09-06 |
| AU2006205029A1 (en) | 2006-07-20 |
| HK1114601A1 (en) | 2008-11-07 |
| DE602006013945D1 (de) | 2010-06-10 |
| EP1846354B1 (en) | 2010-04-28 |
| AR052876A1 (es) | 2007-04-11 |
| NZ555945A (en) | 2011-01-28 |
| IL184025A (en) | 2012-09-24 |
| CN101102989B (zh) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200704739B (en) | Substituted cyclopentanes or cyclopentanones as therapeutic agents | |
| GB0518390D0 (en) | Therapeutic compounds | |
| EP1962961A4 (en) | HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION | |
| GB0518237D0 (en) | Therapeutic compounds | |
| GB0506147D0 (en) | Therapeutic agents | |
| GB0509326D0 (en) | Therapeutic compounds | |
| GB0509573D0 (en) | Therapeutic compounds | |
| GB0518361D0 (en) | Therapeutic compounds | |
| GB0519797D0 (en) | Therapeutic agents | |
| GB0522881D0 (en) | Therapeutic compounds | |
| GB0505725D0 (en) | Therapeutic agents | |
| GB0505437D0 (en) | Therapeutic agents | |
| GB0509405D0 (en) | Therapeutic compounds | |
| GB0519350D0 (en) | Therapeutic agents | |
| GB0518819D0 (en) | Therapeutic agents | |
| GB0518817D0 (en) | Therapeutic agents | |
| GB0513747D0 (en) | Therapeutic compounds | |
| GB0516661D0 (en) | Therapeutic agents | |
| GB0514738D0 (en) | Therapeutic agents | |
| EP1885384A4 (en) | TREATMENT OF LIVER DISEASES | |
| GB0522130D0 (en) | Therapeutic compounds | |
| GB0526107D0 (en) | Therapeutic Compounds | |
| GB0518235D0 (en) | Therapeutic compounds | |
| GB0507003D0 (en) | Therapeutic | |
| GB0518720D0 (en) | Therapeutic combination |